BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Riedemann NC, Habel M, Ziereisen J, Hermann M, Schneider C, Wehling C, Kirschfink M, Kentouche K, Guo R. Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition. Clin Immunol 2017;180:25-32. [PMID: 28366510 DOI: 10.1016/j.clim.2017.03.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Kulkarni HS, Ramphal K, Ma L, Brown M, Oyster M, Speckhart KN, Takahashi T, Byers DE, Porteous MK, Kalman L, Hachem RR, Rushefski M, McPhatter J, Cano M, Kreisel D, Scavuzzo M, Mittler B, Cantu E 3rd, Pilely K, Garred P, Christie JD, Atkinson JP, Gelman AE, Diamond JM. Local complement activation is associated with primary graft dysfunction after lung transplantation. JCI Insight 2020;5:138358. [PMID: 32750037 DOI: 10.1172/jci.insight.138358] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
2 Ricklin D, Mastellos DC, Reis ES, Lambris JD. The renaissance of complement therapeutics. Nat Rev Nephrol 2018;14:26-47. [PMID: 29199277 DOI: 10.1038/nrneph.2017.156] [Cited by in Crossref: 196] [Cited by in F6Publishing: 183] [Article Influence: 39.2] [Reference Citation Analysis]
3 Karasu E, Nilsson B, Köhl J, Lambris JD, Huber-Lang M. Targeting Complement Pathways in Polytrauma- and Sepsis-Induced Multiple-Organ Dysfunction. Front Immunol 2019;10:543. [PMID: 30949180 DOI: 10.3389/fimmu.2019.00543] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
4 Stach L, Dinley EKH, Tournier N, Bingham RP, Gormley DA, Bramhall JL, Taylor A, Clarkson JE, Welbeck KA, Harris CL, Feeney M, Hughes JP, Sepp A, Batuwangala TD, Kitchen SJ, Nichols EM. Novel Selection Approaches to Identify Antibodies Targeting Neoepitopes on the C5b6 Intermediate Complex to Inhibit Membrane Attack Complex Formation. Antibodies (Basel) 2021;10:39. [PMID: 34698051 DOI: 10.3390/antib10040039] [Reference Citation Analysis]
5 Raina R, Vijayvargiya N, Khooblall A, Melachuri M, Deshpande S, Sharma D, Mathur K, Arora M, Sethi SK, Sandhu S. Pediatric Atypical Hemolytic Uremic Syndrome Advances. Cells 2021;10:3580. [PMID: 34944087 DOI: 10.3390/cells10123580] [Reference Citation Analysis]
6 Zelek WM, Xie L, Morgan BP, Harris CL. Compendium of current complement therapeutics. Mol Immunol 2019;114:341-52. [PMID: 31446305 DOI: 10.1016/j.molimm.2019.07.030] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 14.3] [Reference Citation Analysis]
7 Bujko K, Rzeszotek S, Hoehlig K, Yan J, Vater A, Ratajczak MZ. Signaling of the Complement Cleavage Product Anaphylatoxin C5a Through C5aR (CD88) Contributes to Pharmacological Hematopoietic Stem Cell Mobilization. Stem Cell Rev Rep 2017;13:793-800. [PMID: 28918528 DOI: 10.1007/s12015-017-9769-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
8 Harris CL. Expanding horizons in complement drug discovery: challenges and emerging strategies. Semin Immunopathol 2018;40:125-40. [PMID: 28986638 DOI: 10.1007/s00281-017-0655-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
9 Harris CL, Pouw RB, Kavanagh D, Sun R, Ricklin D. Developments in anti-complement therapy; from disease to clinical trial. Mol Immunol 2018;102:89-119. [PMID: 30121124 DOI: 10.1016/j.molimm.2018.06.008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 10.3] [Reference Citation Analysis]
10 Rodrigues PRS, Picco N, Morgan BP, Ghazal P. Sepsis target validation for repurposing and combining complement and immune checkpoint inhibition therapeutics. Expert Opin Drug Discov 2021;16:537-51. [PMID: 33206027 DOI: 10.1080/17460441.2021.1851186] [Reference Citation Analysis]
11 Agostinis C, Balduit A, Mangogna A, Zito G, Romano F, Ricci G, Kishore U, Bulla R. Immunological Basis of the Endometriosis: The Complement System as a Potential Therapeutic Target. Front Immunol 2020;11:599117. [PMID: 33505394 DOI: 10.3389/fimmu.2020.599117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
12 Vlaar APJ, de Bruin S, Brouwer MC, van de Beek D. Efficacy matters: broadening complement inhibition in COVID-19 - Authors' reply. Lancet Rheumatol 2021;3:e95-6. [PMID: 33521673 DOI: 10.1016/S2665-9913(20)30424-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Regal JF, Burwick RM, Fleming SD. The Complement System and Preeclampsia. Curr Hypertens Rep 2017;19:87. [PMID: 29046976 DOI: 10.1007/s11906-017-0784-4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 7.6] [Reference Citation Analysis]
14 Asavapanumas N, Tradtrantip L, Verkman AS. Targeting the complement system in neuromyelitis optica spectrum disorder. Expert Opin Biol Ther 2021;21:1073-86. [PMID: 33513036 DOI: 10.1080/14712598.2021.1884223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Colley CS, Popovic B, Sridharan S, Debreczeni JE, Hargeaves D, Fung M, An LL, Edwards B, Arnold J, England E, Eghobamien L, Sivars U, Flavell L, Renshaw J, Wickson K, Warrener P, Zha J, Bonnell J, Woods R, Wilkinson T, Dobson C, Vaughan TJ. Structure and characterization of a high affinity C5a monoclonal antibody that blocks binding to C5aR1 and C5aR2 receptors. MAbs 2018;10:104-17. [PMID: 28952876 DOI: 10.1080/19420862.2017.1384892] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
16 Zhang L, Fedorov Y, Adams D, Lin F. Identification of complement inhibitory activities of two chemotherapeutic agents using a high-throughput cell imaging-based screening assay. Mol Immunol 2018;101:86-91. [PMID: 29909366 DOI: 10.1016/j.molimm.2018.06.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Ort M, Dingemanse J, van den Anker J, Kaufmann P. Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway. Front Immunol 2020;11:599417. [PMID: 33362783 DOI: 10.3389/fimmu.2020.599417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Fattizzo B, Kulasekararaj AG. Second-Generation C5 Inhibitors for Paroxysmal Nocturnal Hemoglobinuria. BioDrugs 2020;34:149-58. [PMID: 31916226 DOI: 10.1007/s40259-019-00401-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
19 Gupta A, Gupta GS. Status of mannose-binding lectin (MBL) and complement system in COVID-19 patients and therapeutic applications of antiviral plant MBLs. Mol Cell Biochem 2021;476:2917-42. [PMID: 33745077 DOI: 10.1007/s11010-021-04107-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
20 Bauer M, Weyland A, Marx G, Bloos F, Weber S, Weiler N, Kluge S, Diers A, Simon TP, Lautenschläger I, Gründling M, Jaschinski U, Simon P, Nierhaus A, Moerer O, Reill L, Jörres A, Guo R, Loeffler M, Reinhart K, Riedemann N. Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock-A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study). Crit Care Explor 2021;3:e0577. [PMID: 34806021 DOI: 10.1097/CCE.0000000000000577] [Reference Citation Analysis]
21 Vlaar APJ, Lim EHT, de Bruin S, Rückinger S, Pilz K, Brouwer MC, Guo RF, Heunks LMA, Busch MH, van Paassen P, Riedemann NC, van de Beek D. The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19. Clin Transl Sci 2022. [PMID: 35029045 DOI: 10.1111/cts.13213] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Vlaar APJ, de Bruin S, Busch M, Timmermans SAMEG, van Zeggeren IE, Koning R, Ter Horst L, Bulle EB, van Baarle FEHP, van de Poll MCG, Kemper EM, van der Horst ICC, Schultz MJ, Horn J, Paulus F, Bos LD, Wiersinga WJ, Witzenrath M, Rueckinger S, Pilz K, Brouwer MC, Guo RF, Heunks L, van Paassen P, Riedemann NC, van de Beek D. Anti-C5a antibody IFX-1 (vilobelimab) treatment vs best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. Lancet Rheumatol. 2020;2:e764-e773. [PMID: 33015643 DOI: 10.1016/s2665-9913(20)30341-6] [Cited by in Crossref: 48] [Cited by in F6Publishing: 27] [Article Influence: 24.0] [Reference Citation Analysis]
23 Vitiello A, La Porta R, D'Aiuto V, Ferrara F. Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade. Hum Immunol 2021;82:264-9. [PMID: 33632561 DOI: 10.1016/j.humimm.2021.01.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
24 Lim EHT, Vlaar APJ, de-Bruin S, Brouwer MC, van-de-Beek D. Complement inhibition in severe COVID-19 - Blocking C5a seems to be key. EClinicalMedicine 2021;35:100722. [PMID: 33997737 DOI: 10.1016/j.eclinm.2021.100722] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Ghias MH, Hyde MJ, Tomalin LE, Morgan BP, Alavi A, Lowes MA, Piguet V. Role of the Complement Pathway in Inflammatory Skin Diseases: A Focus on Hidradenitis Suppurativa. J Invest Dermatol 2020;140:531-536.e1. [PMID: 31870626 DOI: 10.1016/j.jid.2019.09.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
26 Ricklin D, Barratt-Due A, Mollnes TE. Complement in clinical medicine: Clinical trials, case reports and therapy monitoring. Mol Immunol 2017;89:10-21. [PMID: 28576323 DOI: 10.1016/j.molimm.2017.05.013] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 11.0] [Reference Citation Analysis]
27 Java A, Apicelli AJ, Liszewski MK, Coler-Reilly A, Atkinson JP, Kim AH, Kulkarni HS. The complement system in COVID-19: friend and foe? JCI Insight 2020;5:140711. [PMID: 32554923 DOI: 10.1172/jci.insight.140711] [Cited by in Crossref: 100] [Cited by in F6Publishing: 87] [Article Influence: 50.0] [Reference Citation Analysis]